The Highest Leukaemia-Free Survival After Allogeneic Bone Marrow Transplantation is Seen in Patients with Grade I Acute Graft-Versus-Host Disease

References

• Thomas E. D., Storb R., Clift R. A., Fefer A., Johnson F. L, Neiman P. E., Lerner K. G., Glucksberg H., Buckner C. D. Bone-marrow transplantation I and II. N. Engl. J. Med. 1975; 292: 832–843; 895–902
   PubMed Web of Science ®Google Scholar
• Giralt S. A., Champlin R. E. Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 1994; 84: 3603–3612
   PubMed Web of Science ®Google Scholar
• Weiden P. L., Sullivan K. M., Flournoy N., Storb R., Thomas E. D. the Seattle Marrow Transplant Team. Antileukaemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 1981; 304: 1529–1533
   PubMed Web of Science ®Google Scholar
• Sullivan K. M., Weiden P. L., Storb R., Witherspoon R. P., Fefer A., Fisher L., Buckner C. D., Anasetti C., Appelbaum F. R., Badger C., Beatty P., Bensinger W., Berenson R., Bigelow C., Cheever M. A., Clift R., Deeg H. J., Doney K., Greenberg P., Hansen J. A., Hill R., Loughran T., Martin P., Neiman P., Petersen F. B., Sanders J., Singer J., Stewart P., Thomas E. D. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–1728
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H.-J., Rimm A. A., Ringdén O., Rozman C., Speck B., Truitt R. L., Zwaan F. E., Bortin M. M. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1989; 175: 555–562
   Google Scholar
• Gratwohl A., Hermans J., Apperley K., Arcese W., Bacigalupo A., Bandini G., diBartolomeo P., Boogaerts M., Bosi A., Carreras E., Devergie A., Ferrant A., Fibbe W. E., Frassoni F., Gahrton G., Goldman J., Iriondo A., Jacobsen N., Kolb H. J., Link H., Michalet M., Prentice H. G., Reiffers J., v Rhee F., Ruutu T., Schwaighofer H., Vernant J. P., deWitte T., Niederwieser D. for the Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. (1995). Acute graft-versus-host disease: Grade and outcome in patients with chronic myelogenous leukemia. Blood, 86: 813–818
   PubMed Web of Science ®Google Scholar
• Fefer A., Sullivan K. M., Weiden P., Buckner C. D., Schoch G., Storb R., Thomas E. D. Graft-versus-leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Cellular Immunotherapy of Cancer, R. L. Truitt, R. P. Gale, M. M. Bortin. AR Liss, New York 1987; 401–408
   Google Scholar
• Ringdén O., Zwaan F. E., Hermans J., Gratwohl A. for the Leukemia Working Party of the European Group for Bone Marrow Transplantation. European experience of bone marrow transplantation for leukemia. Transplant. Proc. 1987; 19: 2600–2604
   PubMed Web of Science ®Google Scholar
• Gale R. P., Horowitz M. M., Ash R. C., Champlin R. E., Goldman J. M., Rimm A. A., Ringdén O., Veum J. A., Bortin M. M. Identical twin bone marrow transplants for leukemia. Ann. Int. Med. 1994; 120: 646–652
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Gale R. P., Horowitz M. M., Biggs J. C., Champlin R. E., Gluckman E., Hoffman R. G., Jacobsen S. J., Marmont A. M., McGlave P. B., Messner H. A., Rimm A. A., Rozman C., Speck B., Tura S., Weiner R. S., Bortin M. M. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann. Int. Med. 1988; 108: 806–814
   PubMed Web of Science ®Google Scholar
• Marmont A. M., Horowitz M. M., Gale R. P., Ash R. C., van Bekkum D. W., Champlin R. E., Dicke K. A., Goldman J. M., Good R. A., Herzig R. H., Hong R., Masaoka T., O'Reilly R. J., Prentice H. G., Rimm A. A., Ringdén O., Speck B., Weiner R. S., Bortin M. M. T-cell depletion of HLA-identical transplants in leukemia. Blood 1990; 78: 2120–2130
   Web of Science ®Google Scholar
• Aschan J., Ringdén O., Sundberg B., Klaesson S., Ljungman P., Lönngvist B. Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. Eur. J. Hematol. 1993; 50: 269–274
   PubMed Web of Science ®Google Scholar
• Ringdén O., Labopin M., Gluckman E., Reiffers J., Vernant J. P., Jouet J. P., Harousseau J. L., Garin N. C. For the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Graft versus leukemia effect in allogeneic marrow transplant recipients with acute leukemia treated with cyclosporin combined with methotrexate, Manuscript submitted for publication
   Google Scholar
• Ringdén O., Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40: 39–44
   PubMed Web of Science ®Google Scholar
• Storb R., Deeg H. J., Thomas E. D., Appelbaum F. R., Buckner C. D., Cheeve M. A., Clift R. A., Doney K. C., Flornoy N., Kennedy M. S., Loughran T. P., McGuffin R. W., Gale G. E., Sanders J. E., Singer J. W., Stewart P. S., Sullivan K. M., Witherspoon R. P. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985; 66: 698–702
   PubMed Web of Science ®Google Scholar
• Storb R., Deeg H. J., Whitehead J., Appelbaum F., Beatty P., Bensinger W., Buckner C. D., Clift R., Doney K., Farewell V., Hansen J., Hill R., Lum L., Martin P., McGuffin R., Sanders J., Stewart P., Sullivan K., Witherspoon R., Yee G., Thomas E. D. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N. Engl. J. Med. 1986; 314: 729–735
   PubMed Web of Science ®Google Scholar
• Storb R., Deeg H. J., Pepe M., Appelbaum F., Anasetti C., Beatty P., Bensinger W., Berenson R., Buckner C. D., Clift R, Doney K., Longton G., Hansen J., Hill R., Loughran T., Jr., Martin P., Singer J., Sanders J., Stewart P., Sullivan K. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73: 1729–1734
   PubMed Web of Science ®Google Scholar
• Ringdén O., Horowitz M. M., Sondel P., Gale R. P., Biggs J. G., Champlin R. E., Deeg H. J., Dicke K., Masaoka T., Powles R. L., Rimm A. A., Rozman C., Sobocinski K. A., Speck B., Zwaan F. E., Bortin M. M. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia. Blood 1993; 81: 1094–1101
   PubMed Web of Science ®Google Scholar
• Kaplan E. I., Meier P. Non-parametric estimation for incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Cox D. R., Regression Models, Life tables. J. R. Stat. Soc. Ser. B. 1972; 34: 187–220
   Web of Science ®Google Scholar
• Ringdén O., Sundberg B., Lönngvist B., Tollemar J., Gahrton G., Nilsson B. Allogeneic bone marrow transplantation for leukemia: factors of importance for long-term survival and relapse. Bone Marrow Transplant 1988; 3: 281–290
   PubMed Web of Science ®Google Scholar
• Bacigalupo A., Van Lint M. T., Occhini D. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–1428
   PubMed Web of Science ®Google Scholar
• Aschan J., Ringdén O., Sundberg B., Gahrton G., Ljungman P., Winiarski J. Methotrexate combined with cyclosporine A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991; 7: 113–119
   PubMed Web of Science ®Google Scholar
• Weaver C. H., Hansen J. A., Martin P. O., Sanders J., Sullivan K. M., Thomas E. D., Singer J., Witherspoon R., Buckner C. D. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 1994; 14: 885–893
   PubMed Web of Science ®Google Scholar
• Prentice H. G., Blacklock H. A., Janossy G., Gilmore M. J. M. L., Prince-Jones L., Tidman N., Trejdosiewicz L. K., Skeggs D. B. L., Panjwani O., Ball S., Graphakos S., Patterson J., Ivory K., Hoffbrand A. V. Depletion of T lymphocytes in donor marrow prevents significant graft versus host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1984; i: 472–475
   Google Scholar
• Ringdén O., Remberger M., Aschan J., Ljungman P., Lonngvist B., Markling L. Long-term follow-up of a randomized trial comparing T-cell-depletion with a combination of methotrexate and cyclosporin in adult leukemic marrow transplant recipients. Transplantation 1994; 58: 887–891
   PubMed Web of Science ®Google Scholar
• Naparstek E., Or R., Nagler A., Cividalli G., Engelhard D., Aker M., Gimon Z., Manny N., Sachs T., Tochner Z., Weiss L., Samuel S., Brautbar C., Hale G., Waldmann H., Steinberg S. M., Slavin S. T-cell-depleted allogeneic bone marrow transplantation of acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br. J. Haematol. 1995; 89: 506–515
   PubMed Web of Science ®Google Scholar
• Verdonck L. F., Dekker A. W., de Gast G. C., van Kempen L., Lokhorst, Nieuwenhuis H. K. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 1994; 83: 3090–3096
   PubMed Web of Science ®Google Scholar